Clinical Trial Search

Primary: Cerebral Glutamate Levels — -1.434662171; -1.933853656; -1.412294235; -1.838991525 relative unit (RU as compared to water)

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) — 11; 2; 6; 8 Participants

Primary: Feasibility/Acceptability: Participation Rate — 18; 29 Participants

Primary: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 40.0; 0; 0; 0 percentage of participants

Primary: Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp) — 11.7; 11.5; 12.2; 10.7 mg/kg FFM/min

Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos

Primary: Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal — 269; 23…

Primary: Total Lower Respiratory Symptom Score — 21; 18 score on a scale — p=0.78

Primary: Area Under the Plasma Concentration of BCD-089-time Curve From Zero (0) Hours to 1680 Hours After the Single Subcutaneous Injection of BCD-089 — 0; 15567.9; 44568.6…

Primary: Number of Participants With Progression-free Survival — 17 Participants

Primary: Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT — 55; 115; 125; 120 participants

Primary: Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone — 8.41; 6.77 Months

Primary: Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup — 9.2; 11.2 months — p=0.113

Primary: Average Daily Total Combined Score (TCS) — 10.1; 13.0 units on a scale — p=0.004

Primary: Difference in Functional Reserve of Liver Between Theragnostic SBRT Planning and Standard SBRT Planning — 0.22; 0.02 %/min/m^2